Transforming growth factor β and cardiovascular diseases: The other facet of the 'protective cytokine'

Pharmacological Reports

Volumn 58, Issue 6, 2006, Pages 799-805

  Dabek, Józefa ^a   Kułach, Andrzej ^a   Monastyrska Cup, Barbara ^a   Gasior, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Postinfarct remodeling; Restenosis; Transforming growth factor

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HIRULOG LIKE PEPTIDE; PROSTACYCLIN; SMAD INHIBITOR; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1 ANTAGONIST; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG;

ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; CARDIOVASCULAR DISEASE; ENDOTHELIUM CELL; GENE TRANSFER; GENETIC POLYMORPHISM; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; MACROPHAGE; MONOCYTE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

EID: 33846303229     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Argmann CA, Van Den Diepstraten CH, Sawyez CG, Edwards JY, Hegele RA, Wolfe BM, Huff MW: Transforming growth factor-β1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. Arterioscler Thromb Vasc Biol, 2001, 21, 2011-2018.
2. Ashcroft GS: Bidirectional regulation of macrophage function by TGF-β. Microbes Infect, 1999, 1, 1275-1282.
3. Bijlsma FJ, van der Horst AA, Tilanus MG, Rozemuller E, de Jonge N, Gmelig-Meyling FH, de Weger RA: No association between transforming growth factor beta gene polymorphism and acute allograft rejection after cardiac transplantation. Transpl Immunol, 2002, 10, 43-47.
4. Bobik A: Transforming growth factor-betas and vascular disorders. Arterioscler Thromb Vasc Biol, 2006, 26, 1712-1720.
5. Byrne CD, Wareham NJ, Martensz ND, Humphries SE, Metcalfe JC, Grainger DJ: Increased PAI activity and PAI-1 antigen occurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-β levels. Atherosclerosis, 1998, 140, 45-53.
6. Chen K, Metha JK, Li D, Joseph L, Joseph J: Transforming growth factor-β receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res, 2004, 95, 1167-1173.
7. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH: CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol, 2000, 32, 1805-1819.
8. Dabek J, Mazurek U, Gasior Z, Wilczok T, Kulach A, Kucia-Kuzma S: Transcriptional activity of genes encoding Transforming Growth Factor beta and its receptors in peripheral blood mononuclear cells from patients with acute coronary syndromes. Int J Cardiol, 2006, 111, 275-279.
9. Densem CG, Hutchinson IV, Yonan N, Brooks NH: Donor and recipient - transforming growth factor-beta 1 polymorphism and cardiac transplant-related coronary artery disease. Transpl Immunol, 2004, 13, 211-217.
10. Gojova A, Brun V, Esposito B, Cottrez F, Gourdy P, Ardouin P, Tedgui A et al.: Specific abrogation of transforming growth factor-β signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood, 2003, 102, 4052-4058.
11. Gopalan R, Goldberg S: Tranilast in the therapy of coronary artery disease. Curr Interv Cardiol Rep, 2000, 2, 149-156.
12. Gorelik L, Flavell RA: Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity, 2000, 12, 171-181.
13. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P: Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J, 2002, 21, 1743-1753.
14. Grainger DJ: Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol, 2004, 24, 399-404.
15. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC: Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature, 1994, 370, 460-462.
16. Hansson GK, Robertson AK: TGF-beta in atherosclerosis. Arterioscler Thromb Vasc Biol, 2004, 24, 137.
17. Ikeuchi M, Tsutsui H, Shiomi T, Matsusaka H, Matsushima S, Wen J, Kubota T et al.: Inhibition of TGFbeta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res, 2004, 64, 526-535.
18. Javelaud D, Mauviel A: Mammalian transforming growth factor-betas: smad signaling and physio-pathological roles. Int J Biochem Cell Biol, 2004, 36, 1161-1165.
19. Jinnin M, Ihn H, Tamaki K: Characterization of SIS3, a novel specific inhibitor of smad3 and its effects on transforming growth factor-β1-induced extracellular matrix expression. Mol Pharmacol, 2006, 69, 597-607.
20. Kalinina N, Agrotis A, Antropova Y, Ilyinskaya O, Smirnov V, Tararak E, Bobik A: Smad expression in human atherosclerotic lesions: evidence for impaired TGFbeta/Smad signaling in smooth muscle cells of fibrofatty lesions. Arterioscler Thromb Vasc Biol, 2004, 24, 1391-1396.
21. Khanna A: Concerted effect of transforming growth factor-β cyclin inhibitor p21 and c-myc on smooth muscle cell proliferation. Am J Physiol. 2004, 286, H1133-H1140.
22. Kingston PA, Sinha S, Appleby CE, David A, Verakis T, Castro MG, Lowenstein PR et al: Adenovirus-mediated gene transfer of transforming growth factor-beta3, but not transforming growth factor-beta1, inhibits constrictive remodeling and reduces luminal loss after coronary angioplasty. Circulation, 2003, 108, 2819-2825.
23. Kingston PA, Sinha S, David A, Castro MG, Lowenstein PR, Heagerty AM: Adenovirus-mediated gene transfer of a secreted transforming growth factor-beta type II receptor inhibits luminal loss and constrictive remodeling after coronary angioplasty and enhances adventitial collagen deposition. Circulation, 2001, 104, 2595-2601.
24. Lutgens E, Gijbels M, Smook M, Heeringa P, Gotwals P, Koteliansky VE, Daemen MJ: Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol, 2002, 22, 975-982.
25. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamate C, Merval R, Fradelizi D et al.: Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res, 2001, 89, 930-934.
26. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD et al.: Transforming growth factor-beta induces development of the T(H) 17 lineage. Nature, 2006, 441, 231-234.
27. McCaffrey TA, Consigli S, Du B, Falcone DJ, Sanborn TA, Spokojny AM, Bush HL Jr: Decreased type II/type I TGF-β receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-Β. J Clin Invest, 1995, 96, 2667-2675.
28. Mitani T, Terashima M, Yoshimura H, Nariai Y, Tanigawa Y: TGF-β enhances degradation of IFN-γ-induced iNOS protein via proteasomes in RAW264.7 cells. Nitric Oxide, 2005, 13, 78-87.
29. Miyazono K: Transforming growth factor-beta and its receptors. Nippon Yakurigaku Zasshi, 1996, 107, 133-140.
30. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol, 2002, 2, 933-944.
31. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L: Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J Clin Invest, 1992, 90, 1582-1592.
32. Ota T, Fujii M, Sugizaki T, Ishii M, Miyazawa K, Aburatani H, Miyazono K: Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells. J Cell Physiol, 2002, 193, 299-318.
33. Peng SB, Yan L, Xia X, Watkins SA, Brooks HB, Beight D, Herron DK et al.: Kinetic characterization of novel pyrazole TGFbeta receptor I kinase inhibitors and their blockade of epithalial mesenchymal transition. Biochemistry, 2005, 44, 2293-2304.
34. Piek E, Heldin CH, Dijke PT: Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J, 1999, 13, 2105-2124.
35. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK: Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest, 2003, 112, 1342-1350.
36. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med, 1999, 340, 115-126.
37. Seeland U, Haeuseler C, Hinrichs R; Rosenkranz S, Pfitzner T, Scharffetter-Kochanek K, Bohm M: Myocardial fibrosis in transforming growth factor-beta(1) (TGF-beta(1)) transgenic mice is associated with inhibition of interstitial collagenase. Eur J Clin Invest, 2002, 32, 295-303.
38. Syrris P, Carter ND, Metcalfe JC, Kemp PR, Grainger DJ, Kaski JC, Crossman DC et al.: Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. Clin Sci (Lond), 1998, 95, 659-667.
39. Thompson NL, Bazoberry F, Speir EH, Casscells W, Ferrans VJ, Flanders KC, Kondaiah P et al.: Transforming growth factor beta-1 in acute myocardial infarction in rats. Growth Factors, 1988, 1, 91-99.
40. Turner M, Chantry D, Feldmann M: Transforming growth factor β induces the production of interleukin 6 by human peripheral blood mononuclear cells. Cytokine, 1990, 2, 211-216.
41. Veldhoen M, Stockinger B: TGFbeta1, a 'Jack of all trades': the link with pro-inflammatory IL-17-producing T cells. Trends Immunol, 2006, 27, 358-361.
42. Verrecchia F, Chu ML, Mauviel A: Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/ promoter transactivation approach. J Biol Chem, 2001, 276, 17058-17062.
43. Verrecchia F, Mauviel A: Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol, 2002, 118, 211-215.
44. Wakabayashi K, Suzuki H, Sato T, Iso Y, Katagiri T, Takeyama Y: Eplerenone suppresses neointimal formation after coronary stent implantation in swine. Int J Cardiol, 2006, 107, 260-266.
45. Ward MR, Agrotis A, Kanellakis P, Hall J, Jennings G, Bobik A: Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting. Arterioscler Thromb Vasc Biol, 2002, 22, 940-948.
46. Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y: Association of a T29←C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation, 2000, 101, 2783-2787.
47. Youn TJ, Kim HS, Oh BH: Ventricular remodeling and transforming growth factor-beta 1 mRNA expression after nontransmural myocardial infarction in rats: effects of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor blockade. Basic Res Cardiol, 1999, 94, 246-253.